AVXL Jan 2024 5.000 call
| Previous close | 5.64 |
| Open | 5.64 |
| Bid | 4.30 |
| Ask | 4.80 |
| Strike | 5.00 |
| Expiry date | 2024-01-19 |
| Day's range | 5.64 - 5.64 |
| Contract range | N/A |
| Volume | |
| Open interest | 192 |
- Motley Fool
Wall Street Thinks This Small-Cap Stock Can Quadruple in Value
The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside.
- Zacks
Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome
Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue in the United States.
- GlobeNewswire
Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Kun Jin, Ph.D., as Vice President, Head of Biostatistics. Dr. Jin will draw on h
